Brett Staahl is Co-Founder and VP of Platform at Scribe Therapeutics. Prior to founding Scribe Therapeutics, Staahl was a research associate at Galileo Pharmaceuticals. Shortly after he earned his PhD, Staahl did his postdoc in Jennifer Doudna’s lab, with his work focusing on how gene-editing, particularly CRISPR, could be used to treat Huntington’s disease.
Staahl received his B.A. in Molecular Biology from the University of Colorado, Boulder, and completed his Ph.D. in Developmental Biology at Stanford University in the lab of Prof. Gerald Crabtree. His thesis work elucidated a genetic circuit underlying the switch in subunit composition of the BAF (mSWI/SNF) chromatin-remodeling complex required for neural stem cell differentiation into neurons. He also tested molecular mechanisms for how mutations in this genetic circuit cause neurodevelopmental and neurodegenerative diseases.